Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL>60
2010-019587-36Phase 3Completed
- Sponsor
- Saarland University
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rituximab and vincristine in mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Saarland University. Primary endpoint: Progression-free survival. Started Apr 2011; status: completed.
02
Drugs
rituximabvincristine
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2010-019587-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019587-36.